Two major projects are part of Cork’s € 440m expansion
Merck is expanding its filtration and membrane manufacturing capabilities in Ireland, a move that will create 370 new jobs by 2027.
Merck, a leading science and technology company, will invest approximately € 440 million to expand membrane manufacturing capacity at Carrigtwohill and build a new manufacturing plant at Blarney Business Park, both in Cork, Ireland.
Merck will invest 150 million euros in the construction of a new filtration manufacturing plant at Blarney Business Park. When fully operational, it will increase Merck’s global manufacturing capacity and provide production customers with traditional and novel treatments and therapies.
With the over 290 million euro expansion at Carrigtwohill, Merck has added a manufacturing plant for immersion molding of membranes. These membranes support novel and gene therapies, as well as applications such as virus sterilization, plasma separation, and rapid finger-prick testing. Membranes also serve the business of Process Solutions, which is one of the “Big Three” driving Merck’s growth. Process Solutions purchases products and services for the entire pharmaceutical manufacturing value chain.
Merck aims to increase its group sales to approximately 25 billion euros by 2025. To achieve this growth target, the company will significantly increase its total investments between 2021 and 2025 compared to the period of 2016. -2020.
This announcement follows a € 36 million investment at the same site in 2021 for a second line of lateral flow membrane manufacturing products. Now officially open, this facility makes lateral flow membranes, which are often used in rapid diagnostic testing for rare diseases such as dengue, malaria and Ebola. They are also an important part of rapid antigen testing, which is used for the detection of Covid-19.
Merck’s life sciences business continues to invest in products and technologies in its portfolio that are critical to the development of new therapeutics and vaccines, including single-use solutions, high potency active pharmaceutical ingredients (HP-APIs) and modalities such as antibody-drugs. conjugates (ADC) and viral and gene therapies (VGT).
Over the next five years, Merck will implement investment programs around the world. The target countries are Germany, China, France, Switzerland, Ireland and the United States. All expansion plans include clear targets for energy efficiency, water consumption and waste treatment to help Merck reach its goal of being carbon neutral by 2040, in line with its sustainable growth.
Merck recently announced plans to expand its life sciences business in Wuxi, China; Darmstadt, Germany; Buchs, Switzerland; Molsheim, France, Carlsbad, California, USA; Madison, Wis., USA; Jaffrey, New Hampshire, USA; at Danvers, Massachusetts, USA. These expansions are part of an ambitious multi-year program to increase Merck’s industry capacity and life science capabilities to support the growing worldwide demand for life-saving drugs and make big contribution to public health.
“Ireland is central to our strategy to drive long -term growth and expand our position as a global leader in the life sciences,” said Matthias Heinzel, Merck Board Member and CEO of Life Sciences. “The investment in Cork is the largest single-site investment in the history of our life sciences business and will accelerate the delivery of the essential products, technologies and services our customers need to meet the most challenging conditions of world health, including Covid -19 ”.
Martin McAuliffe, Managing Director and Head of Cork Operations at Merck said: “Today’s announcement of the decision to build a new membrane manufacturing facility at Carrigtwohill and the construction of the new filtration at Blarney is proof of everyone’s skill, hard work and dedication. of our partner here in Cork.Moreover, this is a statement of Merck’s commitment to our operations in Ireland.These new investments ensure a bright future for Merck in Cork and allow us to expand our capabilities here, creating new job opportunities in the technology of the future. ”
IDA Ireland CEO Martin Shanahan said: “This significant investment announced today by Merck, the world’s largest single-site life science and technology company, is well received. This announcement showcases the continued growth and success of Ireland’s life sciences sector and indeed IDA Ireland’s continued commitment to securing jobs and investment for regional sites.
“These Carrigtwohill and Blarney developments will have a significant positive impact on the economy in the Southwest region, both during initial construction and also on the number of full-time jobs that will be created as a result of the expansion. Merck’s decision to increase its presence is certainly proof of the company’s confidence in Ireland’s ability to provide access to world-class talent.I would like to assure the Merck team of IDA Ireland’s continued support and ask them to every success in this important investment. »
Do you like what you see?
Ireland’s ONLY information source dedicated to the distribution and retail channel.
Our editorial mix includes channel news, trend analysis, closed deals, regular channel chat interviews and strategic product insights. This is an important way in which the technology channel can connect and identify new business opportunities.